Sort   by:  
 Page size 
ProteomicsE4F1 and ZNF148 are transcriptional activators of the A57C and wildtype TERT promoter
Point mutations within the TERT promoter are the most common recurrent somatic non-coding mutation identified across different cancer types, including glioblastoma, melanoma, hepatocellular carcinoma and bladder cancer. They are most abundant at C146T and C124T and more rare at A57C, with the latter...
ORGANISM(S): Homo sapiens (Human) 
2023-11-04 | PXD037776 | Pride
Tert promoter mutations Znf148 E4f1 Telomerase 
GenomicsThe transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Reactivation of telomerase reverse transcriptase (TERT) expression enables cells to overcome replicative senescence and escape apoptosis, fundamental steps in the initiation of human cancer. Multiple cancer types, including up to 83% of glioblastomas (GBM), harbor highly recurrent TERT promoter mut...
EGAS00001001242 | EGA
GenomicsInhibiton of the GABPB1L-containing GABP tetramer is sufficient to reverse replicative immortality in TERT promoter mutant glioblastoma cells.
Over 50 types of cancer acquire TERT promoter mutations. These single point mutations reactivate telomerase, allowing for indefinite maintenance of telomere length and enabling cellular immortalization. The transcription factor binding site created by the point mutations specifically recruit the ETS...
EGAS00001002582 | EGA
GenomicsConserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer
Mutations in the TERT promoter are the single most common non-coding mutation in cancer and represent the genetic underpinnings of tumor cell immortality. Beyond the two most common point mutations, G228A and G250A, which selectively recruit the ETS factor GABP to activate TERT, the significance of ...
EGAS00001006118 | EGA
TranscriptomicsTargeted exome sequencing of 69 human melanoma brain metastases
In-depth information regarding the DFCI OncoPanel sequencing panel has been described previously. Briefly, sequencing is performed using an Illumina HiSeq 2500 system (RRID:SCR_016383) with 2×100 paired-end reads. Samples must meet an average 50X coverage and minimum of 30X coverage for 80% of targe...
ORGANISM(S): Homo sapiens 
2024-11-21 | E-MTAB-14575 | biostudies-arrayexpress
GenomicsThe ETS inhibitor YK-4-279 suppresses thyroid cancer progression independent of TERT promoter mutations
The ETS inhibitor YK-4-279 suppresses thyroid cancer progression independent of TERT promoter mutations
PRJNA719780 | ENA
UnknownTERT Promoter Mutations Increase Sense and Antisense Transcription from the TERT Promoter.
Not available
S-EPMC8698883 | biostudies-literature
UnknownTERT promoter mutations in thyroid cancer.
Not available
S-EPMC4750651 | biostudies-literature
UnknownTERT promoter mutations in melanoma survival.
Not available
S-EPMC8238633 | biostudies-literature
UnknownTERT Promoter Mutations and Telomerase in Melanoma.
Not available
S-EPMC9325578 | biostudies-literature
Sort   by:  
 Page size